COMPANY

Innovative Bio Venture developing a new concept of cell therapy

Digital Catalog

Since 2018.
2018 History
SCI Paper & IP
78 R&D Excellence
Equipment
27 R&D Competitiveness

Entr®
(Ultrasound-directed permeation of Environmental transition-guided cellular reprogramming)

Cell reprogramming induction technology of a new paradigm using only ultrasound and environmental control factors

Digital Cell Reprogramming

Automation system for Entr-based cell reprogramming induction

Reprosome®
(A cocktail of reprogramming factors in the exosomes )

Customized exosome containing various cell reprogramming factors induced from human fibroblasts with Entr technology, a core technology of STEMON.

Pipeline

Development of treatments for various intractable diseases using customized Reprosomes induced based on Entr technology

R&D

Research and development
of treatments for
intractable diseases

  • Entr®

  • Digital Cell Reprogramming

  • Reprosome®

  • Pipeline

NEWS

STEMON is adding values
to mankind with the best technology.

Full View
News

STEMON at VIV MEA 2025 with Repropet®!

​STEMON Inc. participated in VIV MEA 2025, held in Abu Dhabi in November 2025, where the company showcased its premium medical device–grade exosome technology for advanced veterinary wound care. At the exhibition, STEMON unveiled Repropet®, a next-generation wound care solution for pets powered by Reprosome®, a high-purity, exosome platform produced through digital reprogramming. The innovative product drew significant interest as a regenerative, science-driven approach to veterinary wound management. As a bio-platform company developing therapeutics for intractable diseases, medical devices, and research-grade exosomes, STEMON will continue expanding global partnerships and advancing digital exosome innovation through its proprietary automated induction system, UltraRepro®.

2025.12.08
News

STEMON Participates in COSMOPROF 2025 in Hong Kong

STEMON Inc. showcased its innovative exosome-based digital bio-platform technologies at COSMOPROF HONG KONG 2025, engaging with global visitors through insightful and inspiring discussions. During the exhibition, STEMON presented UltraRepro®, its automated exosome induction platform, and DDDS®, its digital exosome drug-loading automation system, setting new standards in digitalized biotechnology and gaining strong interest across the cosmetics, medical device, and advanced therapeutic sectors. Building on the meaningful connections made throughout the event, STEMON looks forward to exploring future collaboration opportunities and further strengthening its global leadership in digital bio-innovation.

2025.12.08
News

STEMON Showcases at the CIIE in Shanghai

STEMON Inc. participated in CIIE 2025, held from November 5–10 in Shanghai, where the company showcased its innovative exosome-based technologies. During the exhibition, STEMON presented UltraRepro®, its automated exosome induction system, and DDDS®, a digital exosome drug-loading platform, two breakthrough technologies that bridge beauty, biotechnology, and digital innovation, drawing significant interest from industry experts and visitors. Through its presence at CIIE, STEMON highlighted how premium exosome solutions are shaping the future of beauty and healthcare, while strengthening its global technological leadership.

2025.12.08
News

STEMON Unveils Next-Generation Exosome Technology ‘DDDS’ at Cosmetics 360 Paris

STEMON Showcases ‘DDDS Platform’ and Exosome Technology Loaded with Hyaluronic Acid and PLLA at Cosmetics 360 Paris STEMON showcased its next-generation exosome innovations at the Cosmetics 360 exhibition held in Paris, France, presenting functional plant-derived exosomes loaded with hyaluronic acid (HA) and PLLA, along with the next-generation “Sterile Exosome Bio-Cellulose 5th Generation Mask Pack.”During the exhibition, STEMON drew significant attention by holding business meetings with global beauty leaders such as L’Oréal, LVMH, Proya, and Chanel.In particular, its new product, “BONSOIN Mask Pack,” received high praise as a “next-generation premium mask pack combining innovation and market competitiveness.”Furthermore, STEMON was nominated as a finalist in the Manufacturing Process category of the Cosmetic 360 Awards, a recognition of its technological excellence and innovation in exosome production processes on a global scale. Building on this achievement, STEMON aims to advance toward becoming a global leader in bio-cosmetics under its vision of “Digital beyond Biology.”

2025.10.31